研究报告 Research Report 2 Sep 2024 信达生物 Innovent Biologics (1801 HK) 商业策略稳步执行，运营效率不断提升 The Business Strategy is Being Steadily Executed, and Operational Efficiency is Continuously [Table_yemei 观点聚焦 1] Investment Focus | --- | --- | |----------------------------------------------------------------|------------------------| | | | | | | | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$42.45 | | 目标价 | HK$67.80 | | HTI ESG | 3.6-1.4-3.5 | | E-S-G: 0-5, (Please refer to the Appendix f ...